The role of B7 family molecules in hematologic malignancy

被引：164

作者：

Greaves, Paul ^{[1
]}

Gribben, John G. ^{[1
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, London, England

来源：

BLOOD | 2013年 / 121卷 / 05期

关键词：

REGULATORY T-CELLS; VERSUS-HOST-DISEASE; INDUCED KILLER-CELLS; ANTI-CD80; MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCIBLE COSTIMULATOR ICOS; COLONY-STIMULATING FACTOR; CXC CHEMOKINE RECEPTOR-5; REED-STERNBERG CELLS; IN-VIVO EXPRESSION;

D O I：

10.1182/blood-2012-10-385591

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The B7 family consists of structurally related, cell-surface proteins that regulate immune responses by delivering costimulatory or coinhibitory signals through their ligands. Eight family members have been identified to date including CD80 (B7-1), CD86 (B7-2), CD274 (programmed cell death-1 ligand [PD-L1]), CD273 (programmed cell death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and B7-H6. B7 ligands are expressed on both lymphoid and nonlymphoid tissues. The importance of the B7 family in regulating immune responses is clear from their demonstrated role in the development of immunodeficiency and autoimmune diseases. Manipulation of the signals delivered by B7 ligands shows great potential in the treatment of cancers including leukemias and lymphomas and in regulating allogeneic T-cell responses after stem cell transplantation. (Blood. 2013;121(5):734-744)

引用

页码：734 / 744

页数：11

共 201 条

[1] Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells [J].

Andorsky, David J. ;

Yamada, Reiko E. ;

Said, Jonathan ;

Pinkus, Geraldine S. ;

Betting, David J. ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2011, 17 (13) :4232-4244

[2] Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].

Ansell, Stephen M. ;

Hurvitz, Sara A. ;

Koenig, Patricia A. ;

LaPlant, Betsy R. ;

Kabat, Brian F. ;

Fernando, Donna ;

Habermann, Thomas M. ;

Inwards, David J. ;

Verma, Meena ;

Yamada, Reiko ;

Erlichman, Charles ;

Lowy, Israel ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453

[3] Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia [J].

Aue, Georg ;

Njuguna, Ndegwa ;

Tian, Xin ;

Soto, Susan ;

Hughes, Thomas ;

Vire, Berengere ;

Keyvanfar, Keyvan ;

Gibellini, Federica ;

Valdez, Janet ;

Boss, Carol ;

Samsel, Leigh ;

McCoy, J. Philip, Jr. ;

Wilson, Wyndham H. ;

Pittaluga, Stefania ;

Wiestner, Adrian .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (09) :1266-1273

[4] B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28 [J].

AZUMA, M ;

ITO, D ;

YAGITA, H ;

OKUMURA, K ;

PHILLIPS, JH ;

LANIER, LL ;

SOMOZA, C .

NATURE, 1993, 366 (6450) :76-79

[5] Skint-1 is a highly specific, unique selecting component for epidermal T cells [J].

Barbee, Susannah D. ;

Woodward, Martin J. ;

Turchinovich, Gleb ;

Mention, Jean-Jacques ;

Lewis, Julia M. ;

Boyden, Lynn M. ;

Lifton, Richard P. ;

Tigelaar, Robert ;

Hayday, Adrian C. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (08) :3330-3335

[6] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[7] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Mishra, Anjali ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Becknell, Brian ;

Baiocchi, Robert A. ;

Zhang, Jianying ;

Yu, Jianhua ;

Smith, Megan K. ;

Greenfield, Carli N. ;

Porcu, Pierluigi ;

Devine, Steven M. ;

Rotem-Yehudar, Rinat ;

Lozanski, Gerard ;

Byrd, John C. ;

Caligiuri, Michael A. .

BLOOD, 2010, 116 (13) :2286-2294

[8] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

[9] In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors [J].

Berthon, Celine ;

Driss, Virginie ;

Liu, Jizhong ;

Kuranda, Klaudia ;

Leleu, Xavier ;

Jouy, Nathalie ;

Hetuin, Dominique ;

Quesnel, Bruno .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (12) :1839-1849

[10] Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli [J].

Bertinetti, Cristina ;

Simon, Frederic ;

Zirlik, Katja ;

Heining-Mikesch, Kristina ;

Pfeifer, Dietmar ;

Osterroth, Frank ;

Rosenthal, Felicia M. ;

Veelken, Hendrik .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (05) :395-402

← 1 2 3 4 5 6 7 8 9 10 →